A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 11 Dec 2021)

 

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model
The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public He…
Authors: Lorenzo Argante, Victoria Abbing-Karahagopian, Kumaran Vadivelu, Rino Rappuoli and Duccio Medini
Citation: BMC Infectious Diseases 2021 21:1244
Content type: Research article
Published on: 11 December 2021